Mylan Says Novartis' Lotrel Patent Invalid
By Ben James · November 7, 2007, 12:00 AM EST
Mylan Pharmaceuticals Inc. has struck back at Novartis International AG, claiming that the patent Novartis asserted when it sued Mylan over the hypertension drug Lotrel is invalid....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login